Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 10:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–22 of 22 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Head and Neck Cancer
Interventions
Fenretinide (4-HPR), SCH66336
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Houston, Texas
Conditions
Hutchinson-Gilford Progeria Syndrome
Interventions
Progerinin, Lonafarnib
Drug
Lead sponsor
PRG Science & Technology Co., Ltd.
Industry
Eligibility
1 Year and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Phase 2 Interventional Results available

Lonafarnib for Chronic Hepatitis D

NCT01495585
Conditions
Hepatitis D
Interventions
Lonafarnib, Placebo
Drug · Other
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Hepatitis D
Interventions
Lonafarnib, Ritonavir, Placebo
Drug · Other
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Myelogenous Leukemia, Chronic
Interventions
SCH66336
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
16 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Houston, Texas
Conditions
Progeria
Interventions
Lonafarnib, Zoledronic Acid, and Pravastatin
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Not listed
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Chronic Hepatitis Delta
Interventions
Peginterferon Lambda
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Gliosarcoma, Glioblastoma, Anaplastic Astrocytoma
Interventions
Temodar and SCH 66336
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Progeria, Hutchinson-Gilford Syndrome
Interventions
Lonafarnib, Zoledronic Acid, Pravastatin
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Not listed
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Lung Cancer, Soft Tissue Sarcoma, Colorectal Carcinoma, Breast Cancer, Prostate Cancer
Interventions
Lonafarnib, Docetaxel
Drug
Lead sponsor
Emory University
Other
Eligibility
Not listed
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Brain and Central Nervous System Tumors
Interventions
lonafarnib
Drug
Lead sponsor
Pediatric Brain Tumor Consortium
Network
Eligibility
Up to 21 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
9
States / cities
San Francisco, California • Washington D.C., District of Columbia • Boston, Massachusetts + 6 more
Conditions
Breast Cancer
Interventions
Tumor Sample, Serum Sample
Procedure
Lead sponsor
Hoosier Cancer Research Network
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Indianapolis, Indiana
Conditions
Liver Disease, Hepatitis D
Interventions
Peg-interferon lambda, Lonafarnib, Ritonavir
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Progeria, Hutchinson-Gilford Syndrome
Interventions
Lonafarnib
Drug
Lead sponsor
Monica E. Kleinman
Other
Eligibility
1 Year and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
fluorouracil, leucovorin calcium, lonafarnib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2009
U.S. locations
1
States / cities
New York, New York
Conditions
Hepatitis Delta Virus
Interventions
Lonafarnib, Ritonavir, PEG IFN-alfa-2a, Placebo Lonafarnib, Placebo Ritonavir
Drug
Lead sponsor
Eiger BioPharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
407 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
18
States / cities
Fresno, California • Los Angeles, California • Palo Alto, California + 12 more
Conditions
Progeria
Interventions
Everolimus and lonafarnib
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
18 Months to 25 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Glioblastoma Multiforme
Interventions
Temozolomide and SCH66336
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
Houston, Texas
Conditions
Carcinoma, Squamous Cell, Cancer of Head and Neck
Interventions
SCH66336
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
1
States / cities
Houston, Texas
Conditions
Chronic Myelogenous Leukemia
Interventions
Lonafarnib (SCH66336), Imatinib Mesylate (Gleevec)
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
16 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Houston, Texas
Conditions
Malignant Supratentorial Neoplasm, Recurrent Glioblastoma, Recurrent Gliosarcoma
Interventions
Lonafarnib, Temozolomide
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2025
U.S. locations
1
States / cities
Houston, Texas
Terminated Phase 2 Interventional Results available

Lonafarnib in Metastatic Breast Cancer

NCT00773474
Conditions
Metastatic Breast Cancer
Interventions
Lonafarnib
Drug
Lead sponsor
George Sledge
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
6
States / cities
Galesburg, Illinois • Bloomington, Indiana • Indianapolis, Indiana + 2 more